|Bid||47.04 x 1000|
|Ask||51.34 x 1000|
|Day's Range||48.78 - 50.98|
|52 Week Range||39.07 - 65.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.00|
Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.
In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017. In the first half of the year, Spectrum Pharmaceuticals reported net revenues of $54.7 million compared to $63.4 million in H1 2017.
Today, Arrowhead Pharmaceuticals (ARWR) stock is trading at $20.12, which represents ~42.7% growth from yesterday’s close of $14.10. Arrowhead Pharmaceuticals also hit its 52-week high of $22.39 today.
DSW (NYSE:DSW) jumped more than 20% on a surprisingly strong second-quarter report, while Ionis Pharmaceuticals (NASDAQ:IONS) fell nearly 16% on word that the FDA decided not to approve a drug very similar to the company’s Tegsedi, in trials right now. Stocks charts of Hewlett Packard Enterprise (NYSE:HPE), PG&E (NYSE:PCG) and PepsiCo (NASDAQ:PEP) are the most enticing setups. If the name PG&E rings a bell, it may be because it was featured as one of the top three stock charts back on Aug. 17.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over 40 drugs in development. TEGSEDITM (inotersen) and WAYLIVRATM (volanesorsen) are two antisense drugs that Ionis discovered and successfully advanced through Phase 3 studies.
Portola Pharmaceuticals (PTLA) reported net revenues of $4.0 million in the second quarter. PTLA posted net revenues of $3.8 million in the second quarter of 2017, reflecting ~6.0% YoY (year-over-year) growth. In the first half, Portola Pharmaceuticals reported net revenues of $10.7 million, compared to $8.9 billion in the first half of 2017.
Portola Pharmaceuticals (PTLA) stock closed at $28.74 on August 27, which represents ~2.02% growth from its close of $28.17 on August 24. On August 24, Portola Pharmaceuticals stock witnessed ~9.06% growth to reach $28.17 from its August 23 close of $25.83.
Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. got a rude surprise last night after the Food and Drug Administration issued a complete response letter on their Waylivra, following a contentious vote at a May advisory committee meeting. Peer Alnylam Pharmaceuticals Inc. shares soared yesterday on Pfizer Inc.’s results for a competing treatment for the same disease, ATTR, but in the cardiomyopathy type. Many analysts covering Ionis and Akcea remain optimistic ahead of a FDA decision on Tegsedi, expected by Oct. 6.
Ionis Pharmaceuticals (IONS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks hitting 52-week highs on Aug. 27) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
Yesterday, Alnylam Pharmaceuticals (ALNY) rose ~19% in afternoon trading and closed the day ~16.3% higher than the previous day’s closing price. The rise was triggered by the news of positive phase three study data from Pfizer (PFE) for rival drug tafamidis for the treatment of transthyretin amyloid cardiomyopathy (or ATTR-CM). Alnylam Pharmaceuticals’ ATTR therapy Onpattro (patisiran) was approved by the FDA on August 10, 2018.
Shares of Akcea Therapeutics and Ionis Pharmaceuticals IONS plummeted more than 21 percent and nearly 15 percent, respectively, during after-hours trading after the two companies announced that they had received a complete response letter from the FDA regarding a new drug application for Waylivra. A complete response letter means that the FDA decided that it will not approve the drug in its current form.
Waylivra is one of two drugs Akcea was planning to launch in the next year or two, according to Akcea President Sarah Boyce.
Shares of Akcea Therapeutics Inc. (acka) and Ionis Pharmaceuticals Inc. (ions) dropped in the extended session Monday following a halt after the drug makers said they were disappointed with the Food and Drug Administration's decision over their drug Waylivra. Ionis owns nearly 77% of Akcea's outstanding shares, accorind to FactSet. The companies said they received a "complete response letter" from the Food and Drug Administration concerning their drug Waylivra, a medicine designed to treat a rare liver disorder.
As stocks surged on positive trade news, Tesla slipped after calling off plans to go private, and Pfizer released information that caused big movements in some biotech stocks.
The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease which causes fat accumulation in the ...
Akcea Therapeutics, Inc. (AKCA) an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced that they received a Complete Response Letter (CRL) from the Division of Metabolism and Endocrinology Products of the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for WAYLIVRA™(volanesorsen). “We are extremely disappointed with the FDA’s decision. Familial chylomicronemia syndrome (FCS) is an ultra-rare, devastating hereditary disease that causes unpredictable and potentially fatal acute pancreatitis, chronic complications due to permanent organ damage, and a severe impact on daily living.
Multiple pharma stocks are making sympathy moves Monday in reaction to data released at the 2018 European Society of Cardiology Congress in Munich, Germany. Pfizer Inc. (NYSE: PFE ) shares are trading ...